Cenexi recovery, new product launches and capacity additions power Gland Pharma outlook
Published on: May 21, 2026, 6:20 a.m. | Source: The Economic Times
Gland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving profitability. Future growth is anticipated from capacity expansions and new product lines. The company's contract development and manufacturing business is also expanding. Investors are watching Gland Pharma's growth prospects.
